HLA-C and neoplasm: Our approach to targeting HER2/neu positive tumor cells is to use the same mechanism that the immune system uses to target and kill tumors, that is to target peptides derived from the HER2/neu protein when bound and presented by the Major Histocompatibility Complex (MHC).